Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Dejan Micic

TitleAssistant Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Gastroenterology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ollech JE, Normatov I, Peleg N, Dalal SR, Pekow J, Micic D, Cohen RD, Rubin DT, Sakuraba A. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Jul 24. PMID: 32710391.
      View in: PubMed
    2. Micic D, Wall E, Semrad C. Nutrition Support in the ICU-A Refresher in the Era of COVID-19. Am J Gastroenterol. 2020 Jul 16. PMID: 32694294.
      View in: PubMed
    3. Faust N, Yamada A, Haider H, Komaki Y, Komaki F, Micic D, Sakuraba A. Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis. World J Hepatol. 2020 May 27; 12(5):239-252. PMID: 32547691.
      View in: PubMed
    4. Gondal B, Haider H, Komaki Y, Komaki F, Micic D, Rubin DT, Sakuraba A. Efficacy of various endoscopic modalities in detecting dysplasia in ulcerative colitis: A systematic review and network meta-analysis. World J Gastrointest Endosc. 2020 May 16; 12(5):159-171. PMID: 32477450.
      View in: PubMed
    5. Puello F, Wall E, Herlitz J, Lozano ES, Semrad C, Micic D. Long-Term Outcomes With Teduglutide From a Single Center. JPEN J Parenter Enteral Nutr. 2020 May 11. PMID: 32391948.
      View in: PubMed
    6. Micic D, Oto A, Charlton MR, Benoit JL, Siegler M. Hiding in the Water. N Engl J Med. 2020 May 07; 382(19):1844-1849. PMID: 32374966.
      View in: PubMed
    7. Hamdeh S, Micic D, Hanauer S. Drug-Induced Colitis. Clin Gastroenterol Hepatol. 2020 Apr 30. PMID: 32360808.
      View in: PubMed
    8. Goens D, Micic D. Role of Diet in the Development and Management of Crohn's Disease. Curr Gastroenterol Rep. 2020 Mar 17; 22(4):19. PMID: 32185530.
      View in: PubMed
    9. Akiyama S, Yamada A, Komaki Y, Komaki F, Micic D, Sakuraba A. Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2020 Feb 12. PMID: 32053529.
      View in: PubMed
    10. Wang J, Wamuo O, Micic D. Evaluation of Fibrosis in Intestinal Failure-Associated Liver Disease in the Sustain Registry. JPEN J Parenter Enteral Nutr. 2020 Jan 28. PMID: 31990095.
      View in: PubMed
    11. Rao VL, Micic D, Davis AM. Medical Management of Opioid-Induced Constipation. JAMA. 2019 Nov 04. PMID: 31682706.
      View in: PubMed
    12. Micic D, Sengupta N. Risk Stratification of Angioectasia as a Cause of Gastrointestinal Bleeding: Untangling the Spider's Web? Dig Dis Sci. 2019 10; 64(10):2693-2695. PMID: 31363951.
      View in: PubMed
    13. Micic D, Rao VL, Rubin DT. Clinical Approach to Lactose Intolerance. JAMA. 2019 Sep 26. PMID: 31556907.
      View in: PubMed
    14. Wang J, Eng OS, Micic D. Getting to the Root of the Problem. Gastroenterology. 2020 04; 158(5):1229-1231. PMID: 31560904.
      View in: PubMed
    15. Yamada A, Wang J, Komaki Y, Komaki F, Micic D, Sakuraba A. Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019 08; 50(4):373-385. PMID: 31309607.
      View in: PubMed
    16. Micic D, Rao VL, Semrad CE. Celiac Disease and Its Role in the Development of Metabolic Bone Disease. J Clin Densitom. 2020 Apr - Jun; 23(2):190-199. PMID: 31320223.
      View in: PubMed
    17. Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. Risk of Fractures in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019 07; 53(6):441-448. PMID: 29672437.
      View in: PubMed
    18. Wang Y, Wang J, Pekow J, Dalal S, Cohen RD, Ollech J, Israel A, Shogan BD, Micic D, Cannon L, Umanskiy K, Hurst R, Hyman N, Rubin DT, Sakuraba A. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095. PMID: 31169926.
      View in: PubMed
    19. Rubin JN, Shoag D, Gaetano JN, Micic D, Sengupta N. Risk Factors for 30-day Hospital Readmission for Diverticular Hemorrhage. J Clin Gastroenterol. 2019 04; 53(4):e133-e141. PMID: 28737647.
      View in: PubMed
    20. Micic D, Gaetano JN, Nigam N, Peller M, Rao VL, Semrad C, Stein AC, Kupfer SS. Risk factors for small bowel bleeding in an overt gastrointestinal bleeding presentation after negative upper and lower endoscopy. PLoS One. 2019; 14(2):e0212509. PMID: 30785946.
      View in: PubMed
    21. Micic D, Semrad C, Chopra V. Choosing the Right Central Venous Catheter for Parenteral Nutrition. Am J Gastroenterol. 2019 01; 114(1):4-6. PMID: 30008474.
      View in: PubMed
    22. Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019 01; 53(1):e1-e11. PMID: 28737645.
      View in: PubMed
    23. Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. Risk of Colorectal Cancer in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2018 10; 52(9):796-804. PMID: 28723862.
      View in: PubMed
    24. Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Correction to: Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 10; 63(10):2815. PMID: 30136047.
      View in: PubMed
    25. Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Gastrointestinal cancers in patients with cystic fibrosis - Authors' reply. Lancet Oncol. 2018 08; 19(8):e369. PMID: 30102219.
      View in: PubMed
    26. Micic D, Hirsch A, Setia N, Rubin DT. Enteric infections complicating ulcerative colitis. Intest Res. 2018 Jul; 16(3):489-493. PMID: 30090049.
      View in: PubMed
    27. Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Gastrointestinal cancer risk in cystic fibrosis: more exploration is needed - Authors' reply. Lancet Oncol. 2018 07; 19(7):e333. PMID: 30084376.
      View in: PubMed
    28. Christensen B, Gibson PR, Micic D, Colman RJ, Goeppinger SR, Kassim O, Yarur A, Weber CR, Cohen RD, Rubin DT. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2019 02; 17(3):486-493. PMID: 29751166.
      View in: PubMed
    29. Yamada A, Komaki Y, Komaki F, Micic D, Zullow S, Sakuraba A. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. 2018 06; 19(6):758-767. PMID: 29706374.
      View in: PubMed
    30. Christensen B, Colman RJ, Micic D, Gibson PR, Goeppinger SR, Yarur A, Weber CR, Cohen RD, Rubin DT. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860. PMID: 29562271.
      View in: PubMed
    31. Micic D, Yarur A, Gonsalves A, Rao VL, Broadaway S, Cohen R, Dalal S, Gaetano JN, Glick LR, Hirsch A, Pekow J, Sakuraba A, Walk ST, Rubin DT. Risk Factors for Clostridium difficile Isolation in Inflammatory Bowel Disease: A Prospective Study. Dig Dis Sci. 2018 04; 63(4):1016-1024. PMID: 29417331.
      View in: PubMed
    32. Christensen B, Micic D, Gibson PR, Yarur A, Bellaguarda E, Corsello P, Gaetano JN, Kinnucan J, Rao VL, Reddy S, Singh S, Pekow J, Rubin DT. Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. Aliment Pharmacol Ther. 2018 Mar; 47(6):753-762. PMID: 29377235.
      View in: PubMed
    33. Micic D, McDonald EK, Stein AC, Semrad CE. How to Obtain Training in Nutrition During the Gastroenterology Fellowship. Gastroenterology. 2018 Feb; 154(3):467-470. PMID: 29337152.
      View in: PubMed
    34. Komaki Y, Komaki F, Yamada A, Micic D, Ido A, Sakuraba A. Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. Clin Pharmacol Ther. 2018 02; 103(2):318-331. PMID: 28118483.
      View in: PubMed
    35. Micic D, Gaetano JN, Rubin JN, Cohen RD, Sakuraba A, Rubin DT, Pekow J. Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS One. 2017; 12(8):e0182900. PMID: 28837634.
      View in: PubMed
    36. Lipowska AM, Micic D, Cavallo A, McDonald E. Autoimmune gastrointestinal dysmotility due to small cell lung cancer. BMJ Case Rep. 2017 Aug 11; 2017. PMID: 28801331.
      View in: PubMed
    37. Komaki Y, Komaki F, Micic D, Yamada A, Suzuki Y, Sakuraba A. Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. J Gastroenterol Hepatol. 2017 Jun; 32(6):1143-1151. PMID: 27957761.
      View in: PubMed
    38. Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply. Aliment Pharmacol Ther. 2017 05; 45(10):1372. PMID: 28417494.
      View in: PubMed
    39. Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-a agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 04; 45(8):1043-1057. PMID: 28239873.
      View in: PubMed
    40. Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, Sakuraba A. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-a agents in rheumatic diseases; A systematic review and meta-analysis. J Autoimmun. 2017 May; 79:4-16. PMID: 28209290.
      View in: PubMed
    41. Komaki Y, Komaki F, Micic D, Ido A, Sakuraba A. Risk of colorectal cancer in chronic liver diseases: a systematic review and meta-analysis. Gastrointest Endosc. 2017 Jul; 86(1):93-104.e5. PMID: 28011280.
      View in: PubMed
    42. Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-a use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun. 2017 01; 76:38-52. PMID: 27913060.
      View in: PubMed
    43. Micic D, Hogarth DK, Kavitt RT. Mediastinal granuloma: a rare cause of dysphagia. BMJ Case Rep. 2016 Jun 14; 2016. PMID: 27302638.
      View in: PubMed
    44. Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zerôncio M, Van Assche G, Lee JC, Lindsay JO, Rubin DT, Panaccione R, Colombel JF. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394. PMID: 27282402.
      View in: PubMed
    45. Rao VL, Micic D, Kim KE. Primary Care Evaluation and Management of Gastroenterologic Issues in Women. Obstet Gynecol Clin North Am. 2016 Jun; 43(2):347-66. PMID: 27212096.
      View in: PubMed
    46. Micic D, Semrad CE. Small Bowel Endoscopy. Curr Treat Options Gastroenterol. 2016 Jun; 14(2):220-35. PMID: 27032956.
      View in: PubMed
    47. Gaetano JN, Micic D, Aronsohn A, Reddy G, Te H, Reau NS, Jensen D. The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30. PMID: 26642977.
      View in: PubMed
    48. Micic D, Rao K, Trindade BC, Walk ST, Chenoweth E, Jain R, Trivedi I, Santhosh K, Young VB, Aronoff DM. Serum 25-Hydroxyvitamin D Levels are not Associated with Adverse Outcomes in Clostridium Difficile Infection. Infect Dis Rep. 2015 Aug 11; 7(3):5979. PMID: 26500740.
      View in: PubMed
    49. Natarajan M, Rogers MA, Bundy J, Micic D, Walk ST, Santhosh K, Rao K, Winters S, Young VB, Aronoff DM. Gender Differences in Non-Toxigenic Clostridium difficile Colonization and Risk of Subsequent C. difficile Infection. Clin Res Infect Dis. 2015; 2(2). PMID: 28713874.
      View in: PubMed
    50. Rao VL, Micic D, Rubin DT. Hematochezia and a Mesenteric Mass. Gastroenterology. 2015 Jul; 149(1):e12-3. PMID: 26026749.
      View in: PubMed
    51. Rao K, Micic D, Natarajan M, Winters S, Kiel MJ, Walk ST, Santhosh K, Mogle JA, Galecki AT, LeBar W, Higgins PD, Young VB, Aronoff DM. Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clin Infect Dis. 2015 Jul 15; 61(2):233-41. PMID: 25828993.
      View in: PubMed
    52. Coronel E, Micic D, Rubin DT. Patchy colitis and interstitial lung disease. Gastroenterology. 2015 Jan; 148(1):26-7. PMID: 25450070.
      View in: PubMed
    53. Maranville JC, Micic D, Hanauer SB, Di Rienzo A, Kupfer SS. In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. J Crohns Colitis. 2014 Nov; 8(11):1539-47. PMID: 25052346.
      View in: PubMed
    54. Micic D, Levine MB, Zhao L, Reddy KG. Metastatic Gastric Adenocarcinoma in Cirrhosis. ACG Case Rep J. 2014 Jul; 1(4):199-201. PMID: 26157875.
      View in: PubMed
    55. Corsello PM, Micic D, Rao K, Waljee AK. Challenges in the diagnosis of Clostridium difficile infection. Gastroenterology. 2014 Jun; 146(7):1820-2. PMID: 24768590.
      View in: PubMed
    56. Rao K, Erb-Downward JR, Walk ST, Micic D, Falkowski N, Santhosh K, Mogle JA, Ring C, Young VB, Huffnagle GB, Aronoff DM. The systemic inflammatory response to Clostridium difficile infection. PLoS One. 2014; 9(3):e92578. PMID: 24643077.
      View in: PubMed
    57. Rogers MA, Micic D, Blumberg N, Young VB, Aronoff DM. Storage duration of red blood cell transfusion and Clostridium difficile infection: a within person comparison. PLoS One. 2014; 9(2):e89332. PMID: 24586694.
      View in: PubMed
    58. Micic D, Rubin DT. Describing the clinical phenotypes of Crohn's disease: lessons from the past: commentary on: the broadening conception of regional ileitis. Dig Dis Sci. 2014 Jan; 59(1):6-8. PMID: 24374644.
      View in: PubMed
    59. Rao K, Micic D, Chenoweth E, Deng L, Galecki AT, Ring C, Young VB, Aronoff DM, Malani PN. Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults. J Am Geriatr Soc. 2013 Oct; 61(10):1738-42. PMID: 24083842.
      View in: PubMed
    60. Walk ST, Micic D, Galecki AT, Young VB, Aronoff DM. Understanding increased mortality in Clostridium difficile-infected older adults. Clin Infect Dis. 2013 Aug; 57(4):625-6. PMID: 23658435.
      View in: PubMed
    61. Rao K, Walk ST, Micic D, Chenoweth E, Deng L, Galecki AT, Jain R, Trivedi I, Yu M, Santhosh K, Ring C, Young VB, Huffnagle GB, Aronoff DM. Procalcitonin levels associate with severity of Clostridium difficile infection. PLoS One. 2013; 8(3):e58265. PMID: 23505476.
      View in: PubMed
    62. Walk ST, Micic D, Galecki AT, Rogers MA, Washer L, Newton DW, Malani PN, Young VB, Aronoff DM. Reply to Walker et al. Clin Infect Dis. 2013 Jun; 56(12):1846-7. PMID: 23420819.
      View in: PubMed
    63. Walk ST, Micic D, Galecki AT, Rogers MA, Washer L, Newton DW, Malani PN, Young VB, Aronoff DM. Reply to McDonald. Clin Infect Dis. 2013 Mar; 56(6):907-8. PMID: 23196958.
      View in: PubMed
    64. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, Liu EW, Almassalha LM, Ewing SA, Ring C, Galecki AT, Rogers MA, Washer L, Newton DW, Malani PN, Young VB, Aronoff DM. Clostridium difficile ribotype does not predict severe infection. Clin Infect Dis. 2012 Dec; 55(12):1661-8. PMID: 22972866.
      View in: PubMed
    65. Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, Wiltrout RH. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A. 2009 Nov 17; 106(46):19455-60. PMID: 19892741.
      View in: PubMed
    66. Melander A, Olsson J, Lindberg G, Salzman A, Howard T, Stang P, Lydick E, Emslie-Smith A, Boyle DI, Evans JM, Macdonald TM, Bain J, Sullivan F. 35th Annual Meeting of the European Association for the Study of Diabetes : Brussels, Belgium, 28 September-2 October 1999. Diabetologia. 1999 Aug; 42(Suppl 1):A1-A330. PMID: 27770183.
      View in: PubMed
    Micic's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (235) concept(s)
    _
    Co-Authors Expand Description
    See all (31) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department
    Physical Neighbors Expand Description
    _